AmpiroxicamCAS# 99464-64-9 |
- Tezampanel
Catalog No.:BCC1993
CAS No.:154652-83-2
- Noopept
Catalog No.:BCC1804
CAS No.:157115-85-0
- LY450108
Catalog No.:BCC1725
CAS No.:376594-67-1
- Perampanel
Catalog No.:BCC1847
CAS No.:380917-97-5
- Aniracetam
Catalog No.:BCC4219
CAS No.:72432-10-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 99464-64-9 | SDF | Download SDF |
| PubChem ID | 2176 | Appearance | Powder |
| Formula | C20H21N3O7S | M.Wt | 447.46 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | CP 65703 | ||
| Solubility | DMSO : 50 mg/mL (111.74 mM; Need ultrasonic) | ||
| Chemical Name | ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl]oxy]ethyl carbonate | ||
| SMILES | CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3 | ||
| Standard InChIKey | LSNWBKACGXCGAJ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ampiroxicam(CP65703) is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug.
Target: COX
Ampiroxicam is a non-steroidal anti-inflammatory drug. It is a prodrug of piroxicam. Ampiroxicam inhibits the stretching response in mice induced by phenylbenzoquinone (PBQ) with maximum protective effect (MPE) of 2 mg/kg. Ampiroxicam inhibits swelling in a dose-responsive manner in the rat foot edema (RFE) assay with ED50 of 28 mg/kg at single oral dose and 7.8 mg/kg at 5 daily oral dose. Ampiroxicam blocks primary and secondary lesion development in rat adjuvant arthritis with ED50 of 2.2 mg/kg and 0.5 mg/kg, respectively. Ampiroxicam (3.2 mg/kg) leads to a plasma concentration of 12 μg/mL at a Tmax of 2 hours for piroxicam derived from ampiroxicam in rats [1]. Ultraviolet-A (UVA)-irradiated 1% Ampiroxicam sensitized in guinea pigs shows positive reaction in the patch testing to UVA-irradiated 1% Ampiroxicam and 1% thiosalicylate (TOS). Concentration of Ampiroxicam is easily reduced by the increase in UVA irradiation doses, as compared with that of piroxicam [2]. References: | |||||
Ampiroxicam Dilution Calculator
Ampiroxicam Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2348 mL | 11.1742 mL | 22.3484 mL | 44.6967 mL | 55.8709 mL |
| 5 mM | 0.447 mL | 2.2348 mL | 4.4697 mL | 8.9393 mL | 11.1742 mL |
| 10 mM | 0.2235 mL | 1.1174 mL | 2.2348 mL | 4.4697 mL | 5.5871 mL |
| 50 mM | 0.0447 mL | 0.2235 mL | 0.447 mL | 0.8939 mL | 1.1174 mL |
| 100 mM | 0.0223 mL | 0.1117 mL | 0.2235 mL | 0.447 mL | 0.5587 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ampiroxicam is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug.
- BTZO 1
Catalog No.:BCC7886
CAS No.:99420-15-2
- Methyl rosmarinate
Catalog No.:BCN4536
CAS No.:99353-00-1
- Kadsurin A
Catalog No.:BCN6515
CAS No.:99340-07-5
- Venlafaxine Hydrochloride
Catalog No.:BCC2513
CAS No.:99300-78-4
- Levodropropizine
Catalog No.:BCC4520
CAS No.:99291-25-5
- Proglumide sodium salt
Catalog No.:BCC5768
CAS No.:99247-33-3
- Mulberrofuran G pentaacetate
Catalog No.:BCN6518
CAS No.:99217-75-1
- Broussoflavonol B
Catalog No.:BCN3679
CAS No.:99217-70-6
- Caesalpin J
Catalog No.:BCC8305
CAS No.:99217-67-1
- Kushenol B
Catalog No.:BCN3313
CAS No.:99217-64-8
- Kushenol A
Catalog No.:BCN2982
CAS No.:99217-63-7
- Anpirtoline hydrochloride
Catalog No.:BCC6754
CAS No.:99201-87-3
- 1-Chloroethyl cyclohexyl carbonate
Catalog No.:BCC8463
CAS No.:99464-83-2
- 3-Ethoxy-4-ethoxycarbonyl phenylacetic acid
Catalog No.:BCC8629
CAS No.:99469-99-5
- L-651,582
Catalog No.:BCC7561
CAS No.:99519-84-3
- K 252a
Catalog No.:BCC7152
CAS No.:99533-80-9
- Neuropeptide FF
Catalog No.:BCC5983
CAS No.:99566-27-5
- Sertaconazole
Catalog No.:BCC9146
CAS No.:99592-32-2
- Sertaconazole nitrate
Catalog No.:BCC4716
CAS No.:99592-39-9
- Ondansetron HCl
Catalog No.:BCC2493
CAS No.:99614-01-4
- Ondansetron
Catalog No.:BCC5043
CAS No.:99614-02-5
- Leucanthogenin
Catalog No.:BCN7932
CAS No.:99615-00-6
- Isothymonin
Catalog No.:BCN3393
CAS No.:99615-01-7
- Kazinol B
Catalog No.:BCN4538
CAS No.:99624-27-8
Differential property of antigenic characterization between piroxicam and ampiroxicam in contact hypersensitivity.[Pubmed:10850378]
Res Commun Mol Pathol Pharmacol. 1999;105(1-2):147-54.
Piroxicam (PXM; a non-steroidal anti-inflammatory drug) has been reported to induce photosensitivity. In our previous report, however, ultraviolet-A (UVA)-irradiated or non-irradiated PXM did not induce any reactions in the in vivo model of contact hypersensitivity, while positive patch testing was shown by Ampiroxicam (APX; a prodrug of PXM). The purpose of the present study was to clarify the influence of protein on the antigenicity of PXM using this model. Animals sensitized by UVA-irradiated 1% APX showed positive patch testing (open application) in UVA-irradiated 1% APX, while they were negative in challenge by UVA-irradiated PXM with or without 5% human serum albumin (HSA). Although animals sensitized by 1% thiosalicylate (TOS), which is thought to be an active hapten of PXM, were cross-reacted with UVA-irradiated 1% APX, they failed to react with UVA-irradiated 1% PXM with or without HSA. On the other hand, intra-dermal testing (intra-dermal application) in UVA-irradiated 0.1% PXM with 5% HSA was positive in animals sensitized by UVA-irradiated 1% APX, while 5% HSA alone, 0.1% PXM with 5% HSA and UVA-irradiated 0.1% PXM did not induce any reactions under this condition. Furthermore, concentration of PXM in the presence of HSA was reduced by UVA-irradiation in a time dependent manner, while the degradation of PXM was not observed in the absence of HSA. Finally, PXM almost disappeared at 120 min after the initiation of UVA-irradiation. The degradation of PXM irradiated by UVA was dependent on the concentration of HSA at the range of 0 to 4%. Hence, these results suggest that the presence of protein is necessary for the induction of the antigenic activity of PXM and the antigenic characterization of PXM is different from that of APX in contact hypersensitivity.
Antigenic characterization in ampiroxicam-induced photosensitivity using an in vivo model of contact hypersensitivity.[Pubmed:10527378]
J Dermatol Sci. 1999 Nov;21(3):170-5.
Ampiroxicam (APX), a prodrug of piroxicam (PXM), has been reported to induce photosensitivity. Antigenic characterization of these photosensitivities, however, is still insufficient. The purpose of the present study was to elucidate further mechanism of photosenstivity induced by APX and PXM using an in vivo model of contact hypersensitivity in guinea pigs. Animals sensitized with ultraviolet-A (UVA)-irradiated 1% APX showed positive reaction in the patch testing to UVA-irradiated 1% APX and 1% thiosalicylate (TOS), while they were negative in challenge with UVA-irradiated 1% PXM, non-irradiated APX and PXM, whereas none of UVA-irradiated or non-irradiated APX and PXM showed positive patch test reaction in animals sensitized with UVA-irradiated 1% PXM or control vehicles. Animals sensitized with 1% TOS were successfully challenged by 1% TOS and cross-reacted with UVA-irradiated 1% APX; however, they failed to react with UVA-irradiated PXM, non-irradiated APX and PXM. Indeed, the in vitro study revealed that the concentration of APX was easily reduced by the increase of UVA irradiation dose, as compared with that of PXM. Interestingly, absorption spectrum of UVA-irradiated APX was similar to that of TOS, which is thought to be an active hapten of PXM. In the present study, we succeeded in the development of a novel animal model reflecting the clinical observations. Furthermore, these results suggested that contact hypersensitivity induced by UVA-irradiated APX is developed by photoproducts of APX itself, but not by the biotransformation of APX to PXM.
Preoperative ampiroxicam reduces postoperative pain after hand surgery.[Pubmed:11469844]
J Hand Surg Br. 2001 Aug;26(4):377-9.
We performed a double blind randomised controlled study to assess whether the preoperative administration of Ampiroxicam reduced the level of postoperative pain in 120 patients who underwent surgery to a hand under brachial plexus block. We found that preoperative (pre-emptive) administration of Ampiroxicam significantly reduced the postoperative pain levels and the need for postoperative analgesia.
